
Opinion|Videos|January 31, 2025
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Uveitis risk rises as immune checkpoint inhibitor use expands
2
Laru-zova sustains visual function improvements at 12 months in XLRP gene therapy trial
3
The Retina TL;DR with Dr. Weng: Navigating the ocular risks of facial fillers with Jennifer Murdock, MD
4























